Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation

Shao, Hui; Yang, Shuang; Fonseca, Vivian; Stoecker, Charles; Shi, Lizheng

doi:10.1007/s40273-019-00775-8

Cited by 42 publications

(80 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ordinary least squares regression analysis investigated the correlation between costs of days absent from work and complication indicators, see Equation ( 1 ). Regression analyses have been applied in several studies of diabetes complications [ 6 , 8 , 32 , 33 ]; in our study, the large sample size allowed the use of simple methods as the analyses depend on sample means and variances [ 31 ].…”

Section: Methodsmentioning

confidence: 99%

Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden

et al. 2020

View full text Add to dashboard Cite

Aims/hypothesis The risk of complications and medical consequences of type 2 diabetes are well known. Hospital costs have been identified as a key driver of total costs in studies of the economic burden of type 2 diabetes. Less evidence has been generated on the impact of individual diabetic complications on the overall societal burden. The objective of this study was to analyse costs of hospital-based healthcare (inpatient and outpatient care) and work absence related to individual macrovascular and microvascular complications of type 2 diabetes in Sweden in 2016. Methods Data for 2016 were retrieved from a Swedish national retrospective observational database cross-linking individual-level data for 1997–2016. The database contained information from population-based health, social insurance and socioeconomic registers for 392,200 people with type 2 diabetes and matched control participants (5:1). Presence of type 2 diabetes and of diabetes complications were derived using all years, 1997–2016. Costs of hospital-based care and of absence from work due to diabetes complications were estimated for the year 2016. Regression analysis was used for comparison with control participants to attribute absence from work to individual complications, and to account for joint presence of complications. Results Use of hospital care for complications was higher in type 2 diabetes compared with control participants in 2016: 26% vs 12% had ≥1 hospital contact; there were 86,104 vs 24,608 outpatient visits per 100,000 people; and there were 9894 vs 2546 inpatient admissions per 100,000 people (all p < 0.001). The corresponding total costs of hospital-based care for complications were €919 vs €232 per person (p < 0.001), and 74.7% of costs were then directly attributed to diabetes (€687 per person). Regression analyses distributed the costs of days absent from work across diabetes complications per se, basic type 2 diabetes effect and unattributed causes. Diabetes complications amounted to €1317 per person in 2016, accounting for possible complex interactions (25% of total costs of days absent). Key drivers of costs were the macrovascular complications angina pectoris, heart failure and stroke; and the microvascular complications eye diseases, including retinopathy, kidney disease and neuropathy. Early mortality in working ages cost an additional €579 per person and medications used in risk-factor treatment amounted to €418 per person. Conclusions/interpretation The economic burden of complications in type 2 diabetes is substantial. Costs of absence from work in this study were found to be greater than of hospital-based care, highlighting the need for considering treatment consequences in a societal perspective in research and policy. Graphical abstract

show abstract

Section: Methodsmentioning

confidence: 99%

Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Time spent in each T2DM health state was summed to provide estimates of life expectancy and quality-adjusted life expectancy. We calculated the incremental costs, incremental life-years (LYs), incremental qualityadjusted life-years (QALYs), and incremental cost per LY value for a given year was derived from a baseline utility and applicable regression coefficients as estimated by Shao et al (2019) for (a) complications in the year of an event, (b) history of complications, and (c) demographic characteristics. 26 We added missing regression coefficients for foot ulcer and amputation events by assuming values from a recent diabetes utility study by Sullivan and Ghushchyan (2016).…”

Section: Model Analysismentioning

confidence: 99%

Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes

Guzauskas

Rind

Fazioli

et al. 2021

JMCP

View full text Add to dashboard Cite

BACKGROUND:Oral semaglutide is the first oral formulation of a glucagon-like peptide 1 (GLP-1) receptor agonist to be approved in the United States for glycemic control in people with type 2 diabetes mellitus (T2DM).While oral semaglutide is not indicated for reduction of cardiovascular event risk, its label does include evidence of no increase in cardiovascular risk in people who received oral semaglutide.

show abstract

“…1 As diabetes progresses, it can permanently damage target organs, causing complications such as diabetic nephropathy, heart failure, stroke, angina, and diabetic retinopathy. [2][3][4] T1DM is characterized by irreversible islet β cell destruction resulted from T-cell-mediated autoimmune disorder, which eventually leads to absolute insulin deficiency. 5 Nowadays, diet control, oral hypoglycemic drugs and insulin injection are the most common applied diabetes therapies.…”

Section: Introductionmentioning

confidence: 99%

<p>Cdc42 Promotes ADSC-Derived IPC Induction, Proliferation, And Insulin Secretion Via Wnt/β-Catenin Signaling</p>

Xiao

Huang

Qian

et al. 2019

DMSO

View full text Add to dashboard Cite

Type 1 diabetes mellitus (T1DM) is characterized by irreversible islet β cell destruction. Accumulative evidence indicated that Cdc42 and Wnt/β-catenin signaling both play a critical role in the pathogenesis and development of T1DM. Further, bio-molecular mechanisms in adipose-derived mesenchymal stem cells (ADSCs)-derived insulin-producing cells (IPCs) remain largely unknown. Our aim was to investigate the underlying mechanism of Cdc42/Wnt/β-catenin pathway in ADSC-derived IPCs, which may provide new insights into the therapeutic strategy for T1DM patients. Methods: ADSC induction was accomplished with DMSO under high-glucose condition. ML141 (Cdc42 inhibitor) and Wnt-3a (Wnt signaling activator) were administered to ADSCs from day 2 until the induction finished. Morphological changes were determined by an inverted microscope. Dithizone staining was employed to evaluate the induction of ADSCderived IPCs. qPCR and Western blotting were employed to measure the mRNA and protein expression level of islet cell development-related genes and Wnt signaling-related genes. The proliferation ability of ADSC-derived IPCs was also detected with a cell counting kit (CCK) assay. The expression and secretion of Insulin were detected with immunofluorescence test and enzyme-linked immunosorbent assay (ELISA) respectively. Results: During induction, morphological characters of ADSCs changed into spindle and round shape, and formed islet-line cell clusters, with brown dithizone-stained cytoplasm. Expression levels of islet cell development-related genes were up-regulated in ADSCderived IPCs. Wnt-3a promoted Wnt signaling markers and islet cell development-related gene expression at mRNA and protein levels, while ML141 played a negative effect. Wnt-3a promoted ADSC-derived IPC proliferation and glucose-stimulated insulin secretion (GSIS), while ML141 played a negative effect. Conclusion: Our research demonstrated that DMSO and high-glucose condition can induce ADSCs into IPCs, and Wnt signaling promotes the induction. Cdc42 may promote IPC induction, IPC proliferation and insulin secretion via Wnt/β-catenin pathway, meaning that Cdc42 may be regarded as a potential target in the treatment of T1DM.

show abstract

Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation

Cited by 42 publications

References 41 publications

Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden

Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden

Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes

<p>Cdc42 Promotes ADSC-Derived IPC Induction, Proliferation, And Insulin Secretion Via Wnt/β-Catenin Signaling</p>

Contact Info

Product

Resources

About